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ARTICLE
Mutations in TOP3A Cause a Bloom Syndrome-like Disorder
Carol-Anne Martin,1,26 Kata Sarlo´s,2,26 Clare V. Logan,1,26 Roshan Singh Thakur,2,26 David A. Parry,1
Anna H. Bizard,2 Andrea Leitch,1 Louise Cleal,1 Nadia Shaukat Ali,3 Mohammed A. Al-Owain,4
William Allen,5 Janine Altmu¨ller,6 Miriam Aza-Carmona,7,8 Bushra A.Y. Barakat,3
Jimena Barraza-Garcı´a,7,8 Amber Begtrup,9 Massimo Bogliolo,8,10 Megan T. Cho,9 Jaime Cruz-Rojo,11
Hassan Ali Mundi Dhahrabi,3 Nursel H. Elcioglu,12 GOSgene,13 Gra´inne S. Gorman,14
Rebekah Jobling,15 Ian Kesterton,16 Yoshihito Kishita,17 Masakazu Kohda,17 Polona Le Quesne Stabej,13
Asam Jassim Malallah,3 Peter Nu¨rnberg,6 Akira Ohtake,18 Yasushi Okazaki,17 Roser Pujol,8,10
Maria Jose´ Ramirez,8,10 Anya Revah-Politi,19 Masaru Shimura,20 Paul Stevens,16 Robert W. Taylor,14
Lesley Turner,21 Hywel Williams,13 Carolyn Wilson,5 Go¨khan Yigit,22 Laura Zahavich,15
Fowzan S. Alkuraya,23,27 Jordi Surralles,8,10,24,27 Alejandro Iglesias,25,27 Kei Murayama,20,27
Bernd Wollnik,22,27 Mehul Dattani,13,27 Karen E. Heath,7,8,27 Ian D. Hickson,2,*
and Andrew P. Jackson1,*
Bloom syndrome, caused by biallelic mutations in BLM, is characterized by prenatal-onset growth deficiency, short stature, an erythem-
atous photosensitivemalar rash, and increased cancer predisposition. Diagnostically, a hallmark feature is the presence of increased sister
chromatid exchanges (SCEs) on cytogenetic testing. Here, we describe biallelic mutations in TOP3A in ten individuals with prenatal-
onset growth restriction and microcephaly. TOP3A encodes topoisomerase III alpha (TopIIIa), which binds to BLM as part of the
BTRR complex, and promotes dissolution of double Holliday junctions arising during homologous recombination. We also identify a
homozygous truncating variant in RMI1, which encodes another component of the BTRR complex, in two individuals with microce-
phalic dwarfism. The TOP3A mutations substantially reduce cellular levels of TopIIIa, and consequently subjects’ cells demonstrate
elevated rates of SCE. Unresolved DNA recombination and/or replication intermediates persist into mitosis, leading to chromosome
segregation defects and genome instability thatmost likely explain the growth restriction seen in these subjects and in Bloom syndrome.
Clinical features of mitochondrial dysfunction are evident in several individuals with biallelic TOP3A mutations, consistent with the
recently reported additional function of TopIIIa in mitochondrial DNA decatenation. In summary, our findings establish TOP3Amuta-
tions as an additional cause of prenatal-onset short stature with increased cytogenetic SCEs and implicate the decatenation activity of
the BTRR complex in their pathogenesis.Introduction
Microcephalic primordial dwarfism (MPD) is used
to collectively describe a heterogeneous group of
disorders characterized by significant in utero and
postnatal growth retardation alongside marked micro-
cephaly.1 Bloom syndrome (MIM: 210900) is also associ-
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tous sun-sensitive facial rash that can become evident
during childhood.2 A predisposition to the development
of cancer in early adulthood is also seen, and both
solid tumors and hematological malignancies are a
major cause of early death.3 Additionally, a key cytoge-
netic feature of Bloom syndrome is an increased number
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molecular testing is inconclusive, a finding of elevated
SCEs is currently utilized for diagnostic confir-
mation of Bloom syndrome (see GeneReviews in Web
Resources).
In 1995, Bloom syndrome was shown to be caused by
mutations in BLM (MIM: 604610), which encodes a RecQ
family DNA helicase.5 Mutations in BLM are typically bial-
lelic loss-of-function mutations.6 BLM forms the BTRR
complex with topoisomerase III alpha (TopIIIa) and
RecQ-mediated genome instability proteins 1 and 2
(RMI1 and RMI2, respectively). Together, these proteins
process double Holliday junctions (dHJs) that arise as a
result of homologous-recombination-mediated repair of
double-stranded DNA (dsDNA) breaks during DNA synthe-
sis.7–13 The process of dHJ dissolution requires two steps.
First, the BTRR complex promotes the convergent branch
migration of the dHJ to create a hemicatenane intermedi-
ate, and then this structure is decatenated by TopIIIa in
concert with RMI1 and RMI2.14,15 Dissolution of a dHJ
by this mechanism can be completed without any poten-
tially detrimental exchanges between genetic markers
flanking the original site of homologous recombination.
The alternative processing of dHJs by Holliday junction
resolvases (SLX-MUS81 and GEN1 nucleases) can yield
crossover events, and increased usage of this pathway
has been proposed to explain the increase in SCEs in
BLM-deficient cells.16 Crossover events between homolo-
gous chromosomes can lead to loss of heterozygosity
(LOH),17 which can be detrimental to cell survival and
contribute to increased cancer predisposition.18 Addition-
ally, unresolved recombination intermediates can persist
into mitosis, leading to chromosome bridges, and act as a
source of genome instability.19
Here, we report the identification of pathogenic muta-
tions in TOP3A (MIM: 601243) in ten individuals with
Bloom syndrome-like phenotypic features and characterize
the cellular consequences of these mutations.Material and Methods
Research Subjects
Genomic DNA from the affected individuals and family members
was extracted from peripheral blood by standard methods or ob-
tained from saliva samples with Oragene collection kits according
to the manufacturer’s instructions. Informed consent was ob-
tained from all participating families, and all procedures per-
formed in studies involving human participants were in accor-
dance with the Declaration of Helsinki. Research studies were
approved by the Scottish Multicenter Research Ethics Committee
(05/MRE00/74), the Hospital Universitario La Paz Ethical Commit-
tee (PI-2630), the Great Ormond Street Hospital Research Ethics
Committee (09/H0706/66), the University Medical Center Go¨ttin-
gen Ethics Committee (vote ref. 3/2/1), and the Institute for
Genomic Medicine at Columbia University (protocol AAAO8410).
Parents provided written consent for the publication of
photographs of the affected individuals. For growth measure-
ments, Z scores (standard deviations from population mean for
age and sex) were calculated according to LMS (L, smooth222 The American Journal of Human Genetics 103, 221–231, Augustcurve; M, median; S, coefficient of variation) growth on the basis
of British 1990 growth reference data.20 For calculation of Z scores
for growth measurements published for Bloom syndrome,21 full-
term gestation was assumed, and postnatal growth measurements
were calculated from data provided for the 18- to 21-year age
range.
Exome Sequencing and Sanger Sequencing
Exome sequencing and confirmatory capillary Sanger sequencing
were performed according to standard methodologies as previ-
ously published.22,23 TOP3A and RMI1 variants were annotated
with GenBank: NM_004618.4 and NM_024945.2 reference se-
quences, respectively.
Plasmid Construct and Protein Purification
Cloning of the Mutant hTopIIIa Expression Vector
A plasmid encoding the wild-type (WT) TOP3A cDNA24 was modi-
fied by the Quickchange XL Site-DirectedMutagenesis Kit (Agilent
technologies) with the following primers to recapitulate the dele-
tion and frameshift present in subject P1: 50-CCCTCCGTCACAC
GACTGTGCAGAAGGA-30 (T3_FS_FW) and 50-TCCTTCTGCACA
GTCGTGTGACGGAGGG-30 (T3_FS_RW).
Expression and Purification of TRR
The previously described plasmids encoding RMI1 and RMI213
and hTopoIIIa24 were co-transformed into E. coli Rosetta 2 cells,
and the complex was expressed. The cells were disrupted in buffer
A (50 mM Tris-HCl [pH 7.5], 0.5 M NaCl, 10% glycerol, 0.1%
IGEPAL, 2 mM b-mercaptoethanol, 40 mM imidazole, 1 mM
PMSF, and protease inhibitor tablet [PI, EDTA-free, Roche]) on
ice before dounce homogenization and sonication. After the
removal of cell debris by centrifugation, the lysate was affinity pu-
rified on a 5 mL HisTrap HP affinity column. The complex was
further purified on a 5 mL HiTrap Heparin HP column in buffer
B (50 mM Tris-HCl [pH 7.5], 10% glycerol, 0.1 mM EDTA, and
1 mM DTT) with a linear gradient of 200 mM to 1 M NaCl and
then gel filtered on a 120mLHiLoad 16/600 Superdex 200 column
in buffer B containing 200 mM NaCl. Expression and purification
of the mutant TThr812LeufsTer101RR complex were performed in a
similar manner. BLM was purified as described previously.25,26
dHJ Dissolution
The dHJ substrate construction and dissolution reactions were car-
ried out as described previously.14
Cell Culture
Dermal fibroblasts were obtained by skin-punch biopsy and
were maintained in amnioMAX C-100 complete medium (Life
Technologies) in a 37C incubator with 5%CO2 and 3%O2. siRNA
oligonucleotides (siLUC: 50-CUUACGCUGAGUACUUCGA-30
[siTopIIIa SMARTpool M-005279-01-0005, Dharmacon]) were
transfected into dermal fibroblasts with RNAiMAX (Life Technolo-
gies) according to the manufacturer’s instructions.
Sister Chromatid Exchange Assay
Dermal fibroblasts were treated with 10 mM BrdU for 48 hr fol-
lowed by 0.5 mg/mL colcemid for 2 hr. Metaphases and nuclei
were isolated in hypotonic buffer (0.25% KCl and 1%
Na3C6H5O7), fixed with methanol and acetic acid (3:1 vol/vol),
and dropped onto slides. Dried slides were rehydrated in PBS
and then incubated with 2 mg/mL Hoescht 33342 stain in 23 sa-
line sodium citrate (SSC) buffer (300mMNaCl and 30mM sodium
citrate) for 15 min. Slides were then covered in 23 SSC buffer,2, 2018
Table 1. Identified TOP3A and RMI1 Variants Associated with Microcephalic Dwarfism
Family Individual Gene Biallelic Nucleotide Mutations Predicted Amino Acid Consequence(s) Sex Country of Origin
1 P1 TOP3A c.[2718del];[2718del] p.[Thr907LeufsTer101];[Thr907LeufsTer101] female USA (Czech and Irish
ancestry)
2 P2 TOP3A c.[2271dup];[2271dup] p.[Arg758GlnfsTer3];[Arg758GlnfsTer3] female United Arab Emirates
P3 TOP3A c.[2271dup];[2271dup] p.[Arg758GlnfsTer3];[Arg758GlnfsTer3] female United Arab Emirates
P4 TOP3A c.[2271dup];[2271dup] p.[Arg758GlnfsTer3];[Arg758GlnfsTer3] male United Arab Emirates
3 P5 TOP3A c.[527C>T];[1072_1073dup]a p.[Ala176Val];[Tyr359GlyfsTer17] female Japan
4 P6 TOP3A c.[2271dup];[2271dup] p.[Arg758GlnfsTer3];[Arg758GlnfsTer3] female Syria
5 P7 TOP3A c.[2428del];[2428del] p.[Ser810LeufsTer2];[Ser810LeufsTer2] female Spain
P8 TOP3A c.[2428del];[2428del] p.[Ser810LeufsTer2];[Ser810LeufsTer2] male Spain
6 P9 TOP3A c.[2771dup];[2771dup] p.[Arg758GlnfsTer3];[Arg758GlnfsTer3] male Syria
7 P10 TOP3A c.[2771dup];[2771dup] p.[Arg758GlnfsTer3];[Arg758GlnfsTer3] female Saudi Arabia
8 P11 RMI1 c.[1255_1259del];[1255_1259del] p.[Lys419LeufsTer5]; [Lys419LeufsTer5] female Turkey
P12 RMI1 c.[1255_1259del];[1255_1259del] p.[Lys419LeufsTer5];[Lys419LeufsTer5] female Turkey
– MC1b TOP3A c.[298A>G];[403C>T] p.[Met100Val];[Arg135Ter] female UK
Nomenclature is according to transcript GenBank: NM_004618.4 for TOP3A and GenBank: NM_004618.4 and NM_024945.2 for RMI1.
aClose to donor splice site of exon 10.
bPreviously reported individual with adult-onset mitochondrial disease.32irradiated in ultraviolet A at 5,400 J/m2, dehydrated in an ethanol
series, and mounted in VECTASHIELD with DAPI.
SCE Methodology for Analysis of P7 and P8
Dermal fibroblasts were treated with 26.05 mM BrdU for 72 hr fol-
lowed by 0.5 mg/mL colcemid for 5 hr and then harvested. Cells
were resuspended in a pre-warmed hypotonic solution (0.051 M
KCl) for 20 min at 37C, fixed with methanol and acetic acid
(3:1 vol/vol), and dropped onto slides. Samples were aged for at
least 3 days and then stained with 1.56 mg/mL Hoechst 33258
(Sigma, B2883). Slides were irradiated in 23 SSC with ultraviolet
C (356 nm) at 0.260 J/cm2, washed with 23 SSC, and stained
with 10% Giemsa in phosphate buffer.
SCE analysis of peripheral-blood samples was performed accord-
ing to standard methodology in a diagnostic lab setting.27Immunofluorescence and microscopy
Mitotic abnormalities and G1-associated defects were analyzed as
described previously.28,29 In brief, for mitotic analysis, cells were
seeded onto 22 3 22 mm glass coverslips in 6-well plates. After
18 hr, cells were treated with 3.5 mM RO3306 for 6 hr for the in-
duction of a late G2 arrest and were subsequently released into
fresh media. After 45 min, cells were fixed with 4% paraformalde-
hyde containing 0.2% Triton X-100 in PBS for 20 min. For G1-
associated defects, RO3306-treated cells were released into fresh
media for 30 min. Prometaphase cells were shaken off and re-
seeded onto glass slides coated with poly-L-lysine. After 4–6 hr,
cells were fixed with 4% paraformaldehyde for 10 min and per-
meabilized with 0.5% Triton X-100 for 10 min. Fixed cells were
incubated with antibodies specific to cyclin A (Santa Cruz
Biotechnology, sc-596), 53BP1 (Santa Cruz Biotechnology, sc-
515841), and PICH.30Immunoblotting
Cells were lysed in 50 mM Tris-HCl (pH 8), 280 mM NaCl, 0.5%
NP40, 0.2 mM EDTA, 0.2 mM EGTA, and 10% glycerol supple-The Americmented with a protease inhibitor tablet (Roche Life Science). Pro-
tein samples were run on a 4%–12% NuPAGE Bis-Tris precast gel
(Life Technologies) and then immunoblotted with anti-TopIIIa
raised against amino acids 652–1,001 (Proteintech, 14525-1-AP)
and actin (Sigma, A2066).Results
Identification of Mutations in TOP3A
In ongoing work to identify genes associated withmicroce-
phalic dwarfism, whole-exome sequencing (WES) was per-
formed on subject P1, who had significant microcephaly
and short stature (5.7 and 4.4 standard deviations
[SD], respectively). This identified the homozygous
frameshift mutation c.2718del (p.Thr907LeufsTer101)
(GenBank: NM_004618.4) in TOP3A in chromosomal re-
gion 17p11.2. After interrogation of other cohorts and
clinical contacts made through GeneMatcher,31 we subse-
quently ascertained a further nine individuals from seven
families affected by biallelic deleterious TOP3A variants
that had also been discovered byWES (Table 1). All variants
identified were validated by Sanger capillary sequencing,
and all parents were confirmed to be heterozygous carriers.
Aside from the c.2718del variant (minor allele frequency¼
0.00041%), none of the other variants were reported in
GnomAD.33 Notably, four of the families from the United
Arab Emirates, Syria, and Saudi Arabia (F2, F4, F6, and F7),
were homozygous for the same variant.
Prenatal-Onset Growth Restriction and Microcephaly in
Individuals with TOP3A Mutations
Prenatal growth restriction was evident from the substan-
tially reduced birth weight in all individuals (mean weightan Journal of Human Genetics 103, 221–231, August 2, 2018 223
Table 2. Growth Parameters of Individuals with TOP3A and RMI1 Mutations
Individual
Mutated
Gene
Birth Postnatal
Gestational
Age (Weeks)
Weight OFC Length
Age at Exam
Weight OFC Height
kg
Z Score
(SD)a cm
Z Score
(SD) cm
Z Score
(SD) kg
Z Score
(SD)a cm
Z Score
(SD) cm
Z Score
(SD)
P1 TOP3A 37 1.35 3.9 27.5 4.2 38 5.4 5 months 4.9 2.7 36 5.7 54.8 4.4
P2 TOP3A 37 1.9 2.3 NA NA NA NA 3 years 9.5 3.7 47.5 2.3 84.5 2.8
P3 TOP3A 37 2.2 1.6 NA NA NA NA 8 years 16.5 3.3 49.5 2.9 112.5 2.7
P4 TOP3A 40 2.2 2.9 NA NA NA NA 10 years 18.1 4.6 49.5 3.1 113 4.1
P5 TOP3A 35 1.91 1.3 31.8 0.2 43 1.8 15 years 20 6.4 51 3.1 138 3.7
P6 TOP3A NA 2 NA NA NA NA NA 19 months 5.17 7.5 44.3 3.0 64.3 5.8
P7 TOP3A 38 1.90 2.8 30.0 2.7 41 4.1 3 years, 3 months 7.21 7.0 44.2 5.3 78.7 4.7
P8 TOP3A 34 1.41 2.5 28.5 2.2 42 2.1 7 yearsb 10 2.9 45.8 5.0 98.1 4.5
P9 TOP3A 40 2 3.4 NA NA NA NA 11 years 21.6 3.5 47.5 4.5 125.6 2.7
P10 TOP3A 36 1.6 2.7 NA NA NA NA 4 years, 7 months 9 6.1 45.5 5.0 91 3.3
P11 RMI1 34 1.59 1.7 NA NA NA NA 7 years 14 3.8 46.5 5 100 4
P12 RMI1 38 1.80 3.1 NA NA NA NA 13 years 39 0.9 48 5 135 2.9
MC1c TOP3A NA NA NA NA NA NA NA adult NA NA NA NA 163 NA
Z scores are the standard deviation from population mean for age and sex. The following abbreviation is used: NA, not available.
aAdjusted for gestation.
bGrowth-hormone treatment from 4 years, 3 months of age to 5 years, 11 months of age showed no response.
cPreviously reported individual with adult-onset mitochondrial disease (ataxia and progressive external ophthalmoplegia).322.65 0.9 SD; Table 2 and Figure 1A). Postnatally, weight
(mean 4.85 1.8 SD), height (mean 3.95 1.0 SD), and
occipital-frontal circumference (mean4.05 1.2 SD) were
significantly reduced. Growth parameters were similar to
those previously reported for Bloom syndrome (mean birth
weight 3.75 1.2 SD, mean postnatal weight 3.85 2.1
SD, andmean height3.95 1.1 SD) .21 Althoughmultiple
cafe´-au-lait patches were present in some individuals with
TOP3A mutations, the classical erythematous malar facial
rash was not apparent, and there were no reports of
malignancies (although none had yet reached adulthood;
Table 3 and Figure 1B).
Cardiomyopathy Is Present in Some Individuals with
TOP3A Mutations
A single individual compound heterozygous for rare
TOP3A variants has been reported recently with an
adult-onset mitochondrial disorder (denoted as MC1 in
Table 1).32 Whereas stature was normal (163 cm) in this
adult female, several of the subjects reported here had
clinical features that could also be attributable to mito-
chondrial dysfunction. P3 and P4 (family 2) had an addi-
tional diagnosis of dilated cardiomyopathy, which proved
fatal in P4 at age 10 years. Another brother in this sibship
died as a result of cardiomyopathy at the age of 13 years.
Morphometric and other clinical information are not
available for this individual. In P5 (family 3), a dilated car-
diomyopathy was also reported, and skeletal muscle bi-
opsy demonstrated 87% mitochondrial DNA depletion.
P8 also had asymptomatic left ventricular dilatation224 The American Journal of Human Genetics 103, 221–231, Augustnoted on echocardiography, whereas P9 had hypertro-
phic cardiomyopathy.
Given the identification of multiple individuals with
biallelic deleterious variants in TOP3A, alongside a consis-
tent clinical phenotype across the cohort, we concluded
that these mutations were likely to be pathogenic. We
therefore pursued confirmatory functional studies by em-
ploying both biochemical and cell-biological approaches.
TOP3A Mutations Lead to Markedly Reduced Cellular
Amounts of Enzyme TopIIIa
Most of the identified TOP3A mutations are predicted to
prematurely truncate the encoded protein (Figure 2A) and
hence are likely to have significant effects on cellular pro-
tein amounts.We therefore assessed the amounts of TopIIIa
in primary dermal fibroblast cell lines derived from P1, P7,
and P8. Immunoblotting demonstrated that the amount
of full-length TopIIIawas substantially lower in total cell ly-
sates from all three individuals than in cell lines from unre-
lated control individuals and parents (Figure 2B).
In most subjects, the frameshift mutations would be ex-
pected to result in nonsense-mediated decay of TOP3A
transcripts, explaining the consequent loss of TopIIIa.
However, the homozygous frameshift mutation in P1
(c.2718del [p.Thr907LeufsTer101]) is at the 30 end of the
gene and is not predicted to result in NMD; instead, it
would result in a protein with a length similar to that of
the WT enzyme. The frameshift did, however, result in
abolition of the C-terminal zinc-finger domain, whose pre-
cise cellular function remains to be defined. We therefore2, 2018
Figure 1. Variants in TOP3A Are Associ-
ated with Prenatal-Onset Growth Retar-
dation and Microcephaly
(A) Morphometric data for TOP3A individ-
uals. A global reduction in growth is
evident from before birth. Z scores (stan-
dard deviations from population mean for
age and sex) for birth weight (Wgt), post-
natal weight, height (Hgt), and occipital-
frontal circumference (OFC). Dashed lines
indicate the 95% confidence interval for
the general population. Black circles indi-
cate data points for individuals with
TOP3A mutations. For comparison, gray
bars indicate the mean value for cohorts
of 89 (birth weight), 47 (current weight),
and 52 (current height) subjects with
Bloom syndrome.21
(B) Photographs of facial features of indi-
viduals with TOP3A mutations.expressed recombinant TopIIIaThr907LeufsTer101 in E. coli and
purified it to homogeneity as a complex with the co-ex-
pressed RMI1 and RMI2 in order to characterize it further.
Notably, in contrast to the TRR complex containing Top-
IIIaWT, the complex containing TopIIIaThr907LeufsTer101
(hereafter referred to as TopIIIaP1) exhibited reduced stabil-
ity during purification; lower yields and increased amounts
of degraded products were evident on SDS-PAGE
(Figure 2C). Nevertheless, when used in quantities equi-
molar to those of TopIIIaWT, TopIIIaP1 was proficient in a
biochemical assay for dHJ dissolution when combined
with other components of the BTRR complex. This indi-
cates that this TopIIIa variant retains a near-normal level
of single-stranded DNA (ssDNA) decatenation activity (Fig-
ures 2D–2F). Therefore, we concluded that the major
consequence of the TopIIIaP1 variant, like the other trun-
cating variants, is severe depletion of TopIIIa enzymatic ac-
tivity in cells.
P5 was the only individual we identified to have an
amino acid substitution, p.Ala176Val, that was present in
transwith a frameshift mutation. This amino acid substitu-
tion is absent from GnomAD, and in silico analyses
(MutationTaster, CADD, and SIFT) predict it to be delete-
rious. It is at a highly conserved residue (Figure S1) within
the TOPA domain (Figure 2A) and would therefore be ex-
pected to be highly deleterious to enzymatic function.
Given the above results and that Top3a is a developmen-
tally essential gene in mice,34 we conclude that all of the
identified mutations result in marked but most likely
hypomorphic loss of function of TopIIIa as a result of a
reduction in the cellular amount of the protein. Therefore,
these mutations would be predicted to severely compro-
mise the decatenation activity of the BTRR complex in
dHJ dissolution in vivo. To assess this possibility, we next
pursued cellular assays to assess SCE frequency.
SCEs Are Markedly Elevated in Individuals with TOP3A
Mutations
dHJ can be processed by two pathways; first, dissolution by
the BTRR complex yields non-crossover products only; sec-The Americond, resolution by endonucleases that cleave Holliday
junctions generate both non-crossovers and crossover
products that are visualized as SCEs (Figure 3A). To deter-
mine if dHJ dissolution is impaired in the cells of affected
individuals, we assessed the frequency of SCEs. After
BrdU incorporation, we performed differential sister chro-
matid staining on primary fibroblasts and PHA-stimulated
peripheral blood leukocytes (Figures 3B and 3C). Cells
from individuals with TOP3A mutations had substantially
(3- to 6-fold) more SCEs, than cells from control individ-
uals or heterozygous parents (p < 0.0001 for all affected
individual cell lines; Figure 3C). Therefore, excessive cross-
over recombination was evident in all tested individuals
with TOP3A mutations, indicating that diagnostic cytoge-
netic assessment of SCE levels is predictive of TOP3Amuta-
tions as well as BLM mutations.
Chromosome Segregation Defects and Genome
Instability Occur in Cells with TOP3A Mutations
Impaired dHJ decatenation can result in persistently en-
tangled sister chromatids that impede chromosome segre-
gation at mitosis.19 Therefore, we performed detailed char-
acterization of the mitotic consequences of TopIIIa
deficiency in primary fibroblasts from P1. DAPI staining
demonstrated elevated amounts of chromatin bridges (con-
trol [C] ¼ 0, parent ¼ 0.35 0.4, and P1 ¼ 45 0.6) and lag-
ging chromatin and chromosomes (C ¼ 0.9 5 0.2,
parent ¼ 4 5 0.7, and P1 ¼ 9.2 5 0.9) (Figures 4A and
4B), consistent with persisting chromosome entangle-
ments. Additionally, increased numbers of ultrafine DNA
bridges (UFBs) were revealed by immunostaining for
PICH on DAPI-negative regions19 (C ¼ 2.7 5 0.3, parent
¼ 13.15 1.1, and P1 ¼ 26.75 3.8).
We then examined the post-mitotic consequences of the
observed chromosome segregation errors by enriching for
G1 cells (Figures 4C and 4D). Micronuclei often arise
from chromosome segregation errors,35 and analysis of
DAPI-stained cells demonstrated substantially more micro-
nucleated cells in the P1 fibroblast cell line than in control
and parental cell lines (C ¼ 0.45 0.2, parent ¼ 1.85 0.5,an Journal of Human Genetics 103, 221–231, August 2, 2018 225
Table 3. Clinical Phenotype of Individuals with TOP3A and RMI1 Mutations
TOP3A RMI1
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 MC1 P11 P12
Age 5 months 3 years 8 years 10 years 15 years 19 months 3 years 7 years 11 years 4 years,
7 months
adult 7 years 13 years
Prenatal-onset growth
restriction
yes yes yes yes yes yes yes yes yes yes no yes yes
Elevated sister chromatid
exchange
yes yes yes NA yes NA yes yes yes NA no NA NA
Cafe´-au-lait macules yes yes yes yes no yes no yes yes yes NA no no
Developmental delay mild no no no no milda no mild no mild NA mild no
Cancerb no no no no no no no no no no NA no no
Decreased subcutaneous fat no no no no no no yes yes no yes NA no no
Gastroesophageal reflux yes NA NA NA no yes no NA no NA NA no no
Diabetes mellitus no no no no no no no no no no NA no no
Recurrent infections yesc NA NA NA no no no NA yes yesd NA no no
Malar rash no no no no no no no no no no NA no no
Dilated cardiomyopathy no no yes yes (severe,
deceased)
yes (after heart
transplant)
normal
echocardiogram
NA yese
(asymptomatic)
HCM no NA NA NA
Mitochondrial DNA
depletion in muscle
NA NA NA N/A yes (87%) NA NA NA NA NA yes (>80%) NA NA
Other CDH,
gastrostomy
no abnormal
movements and tics
no hearing loss,
CMAMMA
no no no microcytic
anemiaf
no PEO, ataxia no no
Abbreviations are as follows: CDH, Congenital dislocation of hip; CMAMMA, combinedmalonic andmethylmalonic aciduria (MIM: 614265) due to ACSF3 (MIM: 614245) mutations; HCM, hypertrophic cardiomyopathy; NA,
not available; and PEO, progressive external ophthalmoplegia.
aExpressive speech delay only.
bAll individuals are younger than 15 years old; in Bloom syndrome, neoplasia typically manifests in early adulthood.
cRecurrent otitis media and tonsillitis, leading to tonsillectomy.
dReccurent upper-respiratory-tract infections and oral thrush.
eMild left-ventricle dilatation.
fAnemia due to beta-thalassemia trait.
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Figure 2. Mutations in TOP3A Markedly
Reduce Amounts of TopIIIa but Do Not
Affect Its Intrinsic Decatenation Activity
(A) Schematic of TopIIIa with locations of
variants annotated. Colors are as follows:
red,TOPRIMdomain;purple, TOPAdomain;
and blue, GRF zinc-finger domain.
(B) TOP3Amutations markedly reduce pro-
tein amounts. An immunoblot of a poly-
acrylamide gel is shown and was generated
from total cell lysates from dermal fibro-
blast lines derived from affected individuals
probed with an anti-TopIIIa antibody.
siRNA depletion of TOP3A in a fibroblast
line from control 2 was used to confirm
the specificity of the antibody. C1 and C2
are unrelated control fibroblast lines.
TopIIIa antibody was raised against amino
acids 652–1,001.
(C) Recombinant TopIIIaThr812LeufsTer101
(denoted TopIIIaP1) is less stable than
TopIIIaWT. An immunoblot of a polyacryl-
amide gel is shown and was generated
from purified TopIIIaWT and TopIIIaP1 pro-
teins probed with an anti-TopIIIa antibody.
Protein size markers are 250, 170, 140, 100,
and 70 kDa.
(D) Schematic depicting the BTRR complex
and its role in dHJ dissolution. Homolo-
gous sister chromatids are shown in red
and blue.
(E and F) TopIIIaP1 is proficient for promot-
ing dHJ dissolution with BLM in combina-
tionwith RMI1 and RMI2. (E) Representative polyacrylamide gel demonstrating the enzyme-concentration dependence of the dHJ disso-
lution activity of TopIIIaWTandmutant (TopIIIaP1) TRR complexes with 20 nM BLM at 37C in 30min. TRR was included in reactions at
increasing concentrations ranging from 20 pM to 10 nM. A labeled circular oligonucleotide (lane 1) and dHJ (lane 2) were included as
markers. (F) Quantification of the dHJ dissolution reaction shown in (E). The reaction was repeated twice more with very similar results.and P1 ¼ 7.5 5 1.4). Elevated amounts of 53BP1 nuclear
bodies were also seen in cyclin-A-negative (G1) cells, indi-
cating the transmission of DNA damage from one cell cycle
to the next36 (C ¼ 0.85 0.3, parent ¼ 4.55 0.5, and P1 ¼
115 1.7). Altogether, we conclude that impaired dHJ dec-
atenation in TopIIIa-deficient cells results in both
abnormal recombination and mitotic errors that lead to
accumulation of DNA damage. Because chromatin bridges
and UFBs are also present in individuals affected by Bloom
syndrome,19 these findings are concordant with a shared
disease mechanism.
A Homozygous Truncating Variant in RMI1 Is Associated
with Microcephalic Dwarfism
Finally, throughWESwealso identifiedthehomozygous trun-
cating variant c.1255_1259del (p.Lys419Leufs*5) in RMI1 in
two affected cousins (P11 and P12) from a consanguineous
Turkish family (F8; Table 1 and Figure S3). Both individuals
also had microcephalic dwarfism with a clinical phenotype
and level of growth restriction similar to those of individuals
with TOP3Amutations (Figure 1A and Tables 2 and 3).
Discussion
Here, we report that biallelic mutations in TOP3A cause
prenatal growth restriction, microcephaly, and shortThe Americstature, a clinical phenotype overlapping that seen in
Bloom syndrome. Furthermore, we have identified a
rare RMI1 truncating variant (allele frequency ¼ 1.1 3
105) in two individuals. Given that no homozygous
loss-of-function variants are reported in gnomAD, we
expect this to be the cause of microcephalic dwarfism
in individuals P11 and P12. However, it will be neces-
sary to identify more individuals with other deleterious
sequence variants to establish RMI1 as a disease-related
gene.
Notably, individuals with TOP3A mutations exhibit
elevated amounts of SCEs on cytogenetic testing.
Although cell lines were not available from P11 and P12,
we also predict that increased SCEs will occur in cells
with the homozygous RMI1 p.Lys419Leufs*5 variant given
the important role of this protein in the BTRR com-
plex.9,10,37 For many years, the diagnosis of Bloom syn-
drome rested on a demonstration of elevated SCEs, and
this has continued to be employed in cases where molecu-
lar testing is inconclusive (see GeneReviews in Web Re-
sources). Hence, analysis of other BTRR components is
now warranted when elevated SCEs are detected. Indeed,
given the clear phenotypic overlap between Bloom syn-
drome and individuals with TOP3A mutations, re-evalua-
tion of individuals previously cytogenetically diagnosed
with Bloom syndrome could be fruitful.an Journal of Human Genetics 103, 221–231, August 2, 2018 227
Figure 3. Individuals with TOP3A Mutations Have More SCEs,
Reflecting Chromatid Hyper-recombination
(A) Schematic of dHJ processing. dHJs are either dissolved by the
BTRR complex or alternatively cleaved by structure-specific nucle-
ases that lead to dHJ resolution.
(B and C) BrdU strand-specific labeling of sister chromatids shows
that TOP3A cells have more SCEs than control and parent cells.
(B) Representative images of P1 and parent fibroblast cell lines.
(C) Quantification of SCEs in fibroblast cell lines (P1, P5, P7, and
P8) or PHA-stimulated lymphocytes derived from peripheral-
blood samples (P2 and P3). The median value was plotted with
more than ten metaphase spreads counted per subject. Pairwise
non-parametric Mann Whitney tests were performed against
parental control cells. F1, F2, and F5 SCEs were scored in indepen-
dent laboratories.RMI2 is the fourth component of the BTRR complex.
A single family in which two children were also found
to have elevated SCEs was recently reported to have a
homozygous deletion of RMI2; cafe´-au lait macules
were evident, but only one individual showed mild-228 The American Journal of Human Genetics 103, 221–231, Augustgrowth impairment.38 Because RMI2 is not essential
for BTR (BLM, TopIIIa, and RMI1) enzymatic func-
tion,12 a more subtle cellular and developmental
phenotype might therefore result. It also remains
possible that the BTR complex has functions indepen-
dent of RMI2 given that BLM, TopIIIa, and RMI1 are
conserved in all eukaryotes but RMI2 is absent in inver-
tebrates and yeast.13
Bloom syndrome is associated with a predisposition
to both solid tumors and hematological malignancies.3
However, cancers have not been reported in our indi-
viduals with TOP3A mutations. Nevertheless, all are
still children, and because malignancy in Bloom syn-
drome typically manifests in early adulthood, TOP3A
mutations could also confer an increased risk of
neoplasia.
Distinct from Bloom syndrome, some of our individuals
with TOP3A mutations have clinical features consistent
with mitochondrial dysfunction, and several exhibit a
dilated cardiomyopathy. Notably, an individual with
chronic progressive external ophthalmoplegia and cere-
bellar ataxia, along with a novel functional role for
TopIIIa in the decatenation of mitochondrial DNA after
its replication, has been recently reported32 (denoted as
subject MC1). The compound-heterozygous mutations
c.[298A>G];[403C>T], p.[Met100Val];[Arg135*] could
have milder consequences than those reported in our
cohort, and consistent with this, we found that MC1
does not exhibit short stature (Table 2) or elevated
numbers of SCEs in a primary fibroblast line derived
from this individual (Figure S2). Thus, it appears that
the residual TopIIIa activity in MC1 is sufficient for the
nuclear function of the BTRR complex in dHJ dissolution
and for normal growth but could have become rate
limiting for the role of TopIIIa in mitochondrial DNA
replication.
Mechanistically, our cellular and biochemical studies
suggest that the identified TOP3A mutations reported
here are severe hypomorphs, consistent with the estab-
lished essential cellular and developmental functions
of TopIIIa.34 Given that marked growth restriction
is common in individuals with TOP3A and BLM muta-
tions, it seems likely that they have a shared pathogenic
basis arising from reduced ssDNA decatenation activity
of the BTRR complex. Persistence of unresolved hemi-
catenanes into mitosis leads to the formation of chro-
matin and ultrafine mitotic bridges that have previously
been reported in Bloom syndrome19 and in individuals
with microcephalic dwarfism and condensin muta-
tions.39 The resulting genome instability arising from
persistent chromatin bridges40,41 and micronuclei42
could therefore impair cell viability during development,
causing microcephaly and global growth restriction.
In summary, we demonstrate that mutations in TOP3A
cause microcephalic dwarfism with increased SCE,
implicating the BTRR complex as a cause of growth
disorders.2, 2018
Figure 4. DNA Catenanes Persist into Mitosis in Cells with TOP3A Mutations, Leading to Chromosome Segregation Defects and
Genome Instability
(A and B) Chromosome segregation is impaired in TOP3A-deficient primary fibroblasts. (A) Representative images of chromatin bridges, lag-
ging DNA (DAPI), and UFBs (detected by the presence of PICH and absence of DAPI stain). (B) Quantification of chromatin bridges, lagging
DNA, and PICH-positive UFBs scored in control, parental, and P1 mitotic fibroblasts staged at anaphase B (experimentsR 3, n > 50 cells,
error bars ¼ SEM). To enrich for mitotic cells, we treated fibroblasts with R03306 for 6 hr and released and fixed them after 45 min.
(C) TOP3A P1 fibroblasts display significantly elevated amounts of micronuclei. Top: representative picture of control and P1 fibroblasts.
Bottom: quantification of micronucleus containing interphase cells (experimentsR 3, n> 500, error bars¼ SEM). To enrich for G1 cells,
we released RO3306-treated cells into fresh media for 30 min and collected, re-seeded, and fixed prometaphase cells after 4–6 hr.
(D) P1 fibroblasts with TOP3Amutations display significantly elevated numbers of 53BP1 bodies in G1 nuclei. Top: representative images
of 53BP1 foci (red) and DNA (DAPI). Bottom: quantification of cells with at least four 53BP1 foci in G1 nuclei (negative for cyclin A)
(experimentsR 3, n > 500, error bars ¼ SEM). Scale bar: 2 microns. Two-tailed t test was performed against parent cells.Supplemental Data
Supplemental Data include three figures and one table and can be
found with this article online at https://doi.org/10.1016/j.ajhg.
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